Literature DB >> 8662863

Tamoxifen modulates protein kinase C via oxidative stress in estrogen receptor-negative breast cancer cells.

U Gundimeda1, Z H Chen, R Gopalakrishna.   

Abstract

Nonsteroidal agent tamoxifen (Tam), a therapeutic/chemopreventive agent for breast cancer, inhibits protein kinase C (PKC), which is considered to be one of its extra-estrogen receptor sites of action. This drug is required at higher (>100 microM) concentrations to inhibit PKC in the test tube, whereas it is required at lower (1-10 microM) concentrations to induce inhibition of cell growth in estrogen receptor-negative cell types. To identify additional mechanisms of action of Tam on PKC and cell growth, studies with MDA-MB-231, an estrogen receptor-negative breast carcinoma cell type, have been carried out. Upon treatment with 5-20 microM Tam, a cytosol to membrane translocation of PKC occurred within 30 min, which was then followed by a down-regulation of the enzyme within 2 h. A transient generation of Ca2+/lipid-independent activated form of PKC was observed during this period. Rapidly growing cells require nearly 2-3-fold lower concentrations (2-5 microM) of Tam than do confluent cells to induce changes in PKC. Furthermore, phorbol ester binding observed with intact cells also decreased in Tam-treated cells only under the conditions PKC was inactivated. Unlike phorbol esters, Tam did not directly support the membrane association of PKC. The release of arachidonic acid correlated with the PKC membrane translocation. Studies carried out with [3H]Tam revealed that Tam partitioned into the membrane, and there was no appreciable covalent association of [3H]Tam with cellular proteins within this limited time period (2 h). Various antioxidants (vitamin E, vitamin C, beta-carotene, catalase, and superoxide dismutase) inhibited all these cellular effects of Tam. Moreover, vitamin E strikingly blocked Tam-induced growth inhibition. To determine whether oxymetabolites of Tam can affect PKC permanently, OH-Tam was tested with purified PKC. In contrast to Tam, which reversibly inhibited PKC, OH-Tam permanently inactivated the enzyme by modifying the catalytic domain at lower concentrations. The vicinal thiols present within this domain were found to be required to induce this inactivation. This effect was partially blocked by various antioxidants. This is the first report showing the role of oxidative stress in mediating the actions of Tam. Taken together these results suggest that Tam, by initially partitioning into the membranes, induces a generation of transmembrane signals and an oxidative stress to elicit the membrane association of PKC, followed by an irreversible activation, and subsequent down-regulation of this enzyme, which, in part, may lead to cell growth inhibition.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8662863     DOI: 10.1074/jbc.271.23.13504

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  40 in total

1.  Gynaecological effects of tamoxifen.

Authors:  S M Ismail
Journal:  J Clin Pathol       Date:  1999-02       Impact factor: 3.411

2.  Clinically used selective oestrogen receptor modulators increase LDL receptor activity in primary human lymphocytes.

Authors:  F Cerrato; M E Fernández-Suárez; R Alonso; M Alonso; C Vázquez; O Pastor; P Mata; M A Lasunción; D Gómez-Coronado
Journal:  Br J Pharmacol       Date:  2015-01-08       Impact factor: 8.739

3.  Radiosensitization of human glioma cells by tamoxifen is associated with the inhibition of PKC-ι activity in vitro.

Authors:  Lei Yang; Xiaopeng Yuan; Jie Wang; Cheng Gu; Haowen Zhang; Jiahua Yu; Fenju Liu
Journal:  Oncol Lett       Date:  2015-05-11       Impact factor: 2.967

4.  New piperidine derivative DTPEP acts as dual-acting anti-breast cancer agent by targeting ERα and downregulating PI3K/Akt-PKCα leading to caspase-dependent apoptosis.

Authors:  A Arun; M I Ansari; P Popli; S Jaiswal; A K Mishra; A Dwivedi; K Hajela; R Konwar
Journal:  Cell Prolif       Date:  2018-08-09       Impact factor: 6.831

5.  MEK1/2 inhibition suppresses tamoxifen toxicity on CNS glial progenitor cells.

Authors:  Hsing-Yu Chen; Yin Miranda Yang; Ruolan Han; Mark Noble
Journal:  J Neurosci       Date:  2013-09-18       Impact factor: 6.167

6.  Regulation of aryl hydrocarbon receptor function by selective estrogen receptor modulators.

Authors:  Carolyn D DuSell; Erik R Nelson; Bryan M Wittmann; Jackie A Fretz; Dmitri Kazmin; Russell S Thomas; J Wesley Pike; Donald P McDonnell
Journal:  Mol Endocrinol       Date:  2009-11-09

7.  Tamoxifen modulation of etoposide cytotoxicity involves inhibition of protein kinase C activity and insulin-like growth factor II expression in brain tumor cells.

Authors:  Cheppail Ramachandran; Ziad Khatib; Athena Petkarou; John Fort; Hugo B Fonseca; Steven J Melnick; Enrique Escalon
Journal:  J Neurooncol       Date:  2004 Mar-Apr       Impact factor: 4.130

8.  Tocotrienols inhibit the growth of human breast cancer cells irrespective of estrogen receptor status.

Authors:  K Nesaretnam; R Stephen; R Dils; P Darbre
Journal:  Lipids       Date:  1998-05       Impact factor: 1.880

9.  Tamoxifen enhances the cytotoxic effects of nelfinavir in breast cancer cells.

Authors:  Ansgar Brüning; Klaus Friese; Alexander Burges; Ioannis Mylonas
Journal:  Breast Cancer Res       Date:  2010-07-01       Impact factor: 6.466

10.  Chronic tamoxifen use is associated with a decreased risk of intestinal metaplasia in human gastric epithelium.

Authors:  Chang Mo Moon; Seok-Hyung Kim; Sang Kil Lee; Jiyeon Hyeon; Ja Seung Koo; Sangheun Lee; Jean S Wang; Won Jae Huh; Shradha S Khurana; Jason C Mills
Journal:  Dig Dis Sci       Date:  2013-12-25       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.